Non-Hodgkin Lymphoma | Specialty

Emerging Therapies for R/R DLBCL

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

Prognosis of R/R DLBCL

July 15th 2020

Standard of Care for Treatment of DLBCL

July 15th 2020

Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL

July 14th 2020

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

EMA Accepts Application for Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

The European Medicines Agency has validated and accepted a marketing authorization application for zanubrutinib for the treatment of patients with Waldenström macroglobulinemia who have received at least 1 prior therapy or as frontline treatment for patients who are ineligible for chemoimmunotherapy.

Dr. Jacobson on Design of ZUMA-5 Trial in R/R Indolent Non-Hodgkin Lymphoma

June 18th 2020

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

FDA Approves Tazemetostat in Relapsed/Refractory Follicular Lymphoma

June 18th 2020

The FDA has approved tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as those with relapsed/refractory disease who have no other available satisfactory treatment options.

Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 12th 2020

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

FDA Grants CLR 131 Fast Track Status for LPL/WM

May 26th 2020

The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

More Data Needed to Tease Out Optimal Approaches in Non-Hodgkin Lymphoma

May 7th 2020

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

FDA Extends Review Period for Liso-Cel in Large B-Cell Lymphoma

May 6th 2020

The FDA has extended the review period for a biologics license application for lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Devimistat Development Progresses in Relapsed/Refractory Burkitt Lymphoma

April 29th 2020

Ariela Noy, MD, discusses the rationale and design of the phase 2 study of devimistat in patients with aggressive lymphoma.